Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease
Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice
Objective: To identify cell-specific and dynamical modifications of signaling pathways associated with PD and drug-induced modifications Background: Parkinson's disease (PD) is characterized by severe locomotor…Case report: Chorea-acynthocytosis with two compoud heterozygous VPS13A large deletions
Objective: We report a 33 year old male patient without functional protein due to compound heterozygosity for VPS13A deletions and discuss the molecular diagnostic difficulties…K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease
Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model
Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches
Objective: To validate effect of Indolocarbazole derivatives on Cyclin dependent kinase for treating Parkinson's (Preliminary work in context of CDK5 assay and Simulations have been…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.